Research Publications:@0.674285:0.063855:0.896201:0.063855:0.896201:0.040840:0.674285:0.040840:0.016980:0.010442:0.009149:0.010442:0.011759:0.010014:0.010442:0.013076:0.005456:0.014370:0.013076:0.013076:0.006538:0.006538:0.010442:0.011759:0.007832:0.006538:0.011759:0.013076:0.009149
Design, Synthesis, In Vitro, And In Silico Studies Of New N5-:@0.104762:0.111208:0.847657:0.111208:0.847657:0.083261:0.104762:0.083261:0.020619:0.012680:0.011109:0.007939:0.014279:0.015878:0.007140:0.007140:0.015878:0.014279:0.015878:0.009510:0.015878:0.012680:0.011109:0.007939:0.011109:0.007140:0.007140:0.011109:0.015878:0.006651:0.019562:0.007939:0.009510:0.012157:0.014279:0.007140:0.005563:0.020619:0.015878:0.015878:0.007140:0.011109:0.015878:0.007140:0.015878:0.007939:0.007939:0.007939:0.012680:0.014279:0.007140:0.015878:0.009510:0.015878:0.015878:0.007939:0.012680:0.011109:0.007140:0.022218:0.009510:0.007140:0.020619:0.012680:0.020619:0.007140:0.020619:0.014279:0.009510
Substituted-Pyrazolo[3,4-D]Pyrimidinone Derivatives As :@0.104762:0.137337:0.802781:0.137337:0.802781:0.109391:0.104762:0.109391:0.015878:0.015878:0.015878:0.011109:0.009510:0.007939:0.009510:0.015878:0.009510:0.012680:0.015878:0.009510:0.017449:0.014279:0.012680:0.014279:0.012680:0.014279:0.007939:0.014279:0.009510:0.014279:0.007140:0.014279:0.009510:0.020619:0.009510:0.017449:0.014279:0.012680:0.007939:0.023789:0.007939:0.015878:0.007939:0.015878:0.014279:0.015878:0.012680:0.007131:0.020619:0.012680:0.012680:0.007939:0.014279:0.014279:0.009510:0.007939:0.014279:0.012680:0.011109:0.005549:0.020619:0.011109:0.007140
Anticancer Cdk2 Inhibitors :@0.104762:0.163466:0.449333:0.163466:0.449333:0.135520:0.104762:0.135520:0.020619:0.015878:0.009510:0.007939:0.012680:0.014279:0.015878:0.012680:0.012680:0.012154:0.007140:0.020619:0.015878:0.015878:0.014279:0.007140:0.011109:0.015878:0.015878:0.007939:0.015878:0.007939:0.009510:0.014279:0.012680:0.011109:0.007140
Pharmaceuticals. 2023; 16(11): 1593.:@0.318546:0.188085:0.682406:0.188085:0.682406:0.165818:0.318546:0.165818:0.014370:0.013076:0.011759:0.009149:0.018297:0.011759:0.010442:0.010442:0.013076:0.006538:0.006538:0.010442:0.011759:0.006538:0.009149:0.005880:0.005880:0.011759:0.011759:0.011759:0.011759:0.007832:0.005880:0.011759:0.011759:0.007832:0.010447:0.011759:0.007832:0.007832:0.005880:0.011759:0.011759:0.011759:0.011759:0.005880
------------------------------------------------------------------------------------:@0.171532:0.214209:0.829392:0.214209:0.829392:0.191810:0.171532:0.191810:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832
Waheed A. Zaki, Selwan M El-Sayed, Mohamed Alswah, Ahmed El-Morsy, Ashraf H. :@0.116541:0.239984:0.889863:0.239984:0.889863:0.219308:0.116541:0.219308:0.017796:0.010919:0.012142:0.009696:0.009696:0.010919:0.004647:0.014566:0.005460:0.005460:0.013343:0.010919:0.010919:0.006071:0.005460:0.005460:0.012142:0.009696:0.006071:0.014566:0.010919:0.012142:0.005460:0.019415:0.005460:0.014566:0.006071:0.007272:0.012142:0.010919:0.009696:0.009696:0.010919:0.005460:0.005460:0.019415:0.010919:0.012142:0.010919:0.016990:0.009696:0.010919:0.004636:0.014566:0.006071:0.008495:0.014566:0.010919:0.012142:0.005460:0.004654:0.014566:0.012142:0.016990:0.009696:0.010919:0.005460:0.014566:0.006071:0.007272:0.019415:0.010919:0.008495:0.008495:0.008884:0.005460:0.004649:0.014566:0.008495:0.012142:0.008495:0.010919:0.007272:0.005460:0.016990:0.005460:0.005460
Bayoumi, Abrahman S. Mayhoub, Walaa H. Moustafa, Aeshah A. Awaji, Eun Joo Roh, :@0.108286:0.266111:0.898121:0.266111:0.898121:0.245434:0.108286:0.245434:0.014566:0.010919:0.009696:0.010919:0.012142:0.016990:0.006071:0.005460:0.004643:0.014566:0.010919:0.008495:0.010919:0.012142:0.016990:0.010919:0.012142:0.005460:0.012142:0.005460:0.005460:0.019415:0.010919:0.009696:0.012142:0.010919:0.012142:0.010919:0.005460:0.005080:0.017798:0.010919:0.006071:0.010919:0.010919:0.005460:0.016990:0.005460:0.005460:0.019415:0.010919:0.012142:0.008495:0.006071:0.010919:0.007272:0.010919:0.005460:0.004647:0.014566:0.009696:0.008495:0.012142:0.010919:0.012142:0.004656:0.014566:0.005460:0.004649:0.012946:0.014566:0.010919:0.006071:0.006071:0.005460:0.005460:0.014566:0.012142:0.012142:0.005460:0.010919:0.010919:0.010919:0.005460:0.014566:0.010919:0.012142:0.005460:0.005460
Ahmed H.e. Hassan, Kazem Mahmoud:@0.324837:0.292237:0.676133:0.292237:0.676133:0.271561:0.324837:0.271561:0.014566:0.012142:0.016990:0.009696:0.010919:0.005460:0.016990:0.005460:0.009696:0.005460:0.005460:0.016990:0.010919:0.008495:0.008495:0.010919:0.012142:0.005460:0.005460:0.014566:0.010919:0.008495:0.009696:0.016990:0.005460:0.019415:0.010919:0.012142:0.016990:0.010919:0.012142:0.010919
Vol. 2 - Issue 1:@0.743337:0.965677:0.857137:0.965677:0.857137:0.947594:0.743337:0.947594:0.011649:0.009239:0.005137:0.004620:0.004620:0.009239:0.004620:0.006153:0.004620:0.007188:0.007188:0.007188:0.010274:0.008205:0.004620:0.009239
Reference::@0.104762:0.641333:0.210548:0.641333:0.210548:0.619066:0.104762:0.619066:0.015687:0.010442:0.007832:0.010442:0.009149:0.010442:0.013076:0.010442:0.010442:0.007832
https://doi.org/10.3390/ph16111593 :@0.104762:0.660862:0.350068:0.660862:0.350068:0.644862:0.104762:0.644862:0.008399:0.004670:0.004670:0.008399:0.006535:0.004670:0.004670:0.004670:0.008399:0.008399:0.004670:0.004200:0.008399:0.005277:0.008399:0.004670:0.008399:0.008399:0.004200:0.008399:0.008399:0.008399:0.008399:0.004670:0.008399:0.008399:0.008399:0.008399:0.007771:0.007775:0.008399:0.008399:0.008399:0.008399:0.004200
Abstract:@0.104762:0.323088:0.213026:0.323088:0.213026:0.295141:0.104762:0.295141:0.020905:0.016164:0.011395:0.009795:0.012965:0.014565:0.012965:0.009510
CDK2 is a key player in cell cycle processes. It has a crucial role in the progression of various :@0.104762:0.344679:0.900471:0.344679:0.900471:0.325479:0.104762:0.325479:0.013647:0.014756:0.014756:0.010281:0.005886:0.005806:0.008043:0.005886:0.009152:0.005886:0.010281:0.009152:0.010281:0.005886:0.010281:0.005806:0.009152:0.010281:0.009152:0.006914:0.005886:0.005806:0.010281:0.005886:0.009152:0.009152:0.005806:0.005806:0.005886:0.009152:0.010281:0.009152:0.005806:0.009152:0.005886:0.010281:0.006914:0.010281:0.009152:0.009152:0.008043:0.008043:0.009152:0.008043:0.005241:0.005886:0.006914:0.005806:0.005886:0.010281:0.009152:0.008043:0.005886:0.009152:0.005886:0.009152:0.006914:0.010281:0.009152:0.005806:0.009152:0.005806:0.005886:0.006914:0.010281:0.005806:0.009152:0.005886:0.005806:0.010281:0.005886:0.005806:0.010281:0.009152:0.005886:0.010281:0.006914:0.010281:0.010281:0.006914:0.009152:0.008043:0.008043:0.005806:0.010281:0.010281:0.005886:0.010281:0.006914:0.005886:0.010281:0.009152:0.006914:0.005806:0.010281:0.010281:0.007846:0.005040
cancers. Hepatocellular carcinoma (HCC) and colorectal cancer (CRC) are two common cancers :@0.104762:0.361783:0.900309:0.361783:0.900309:0.342584:0.104762:0.342584:0.009152:0.009152:0.010281:0.009152:0.009152:0.006914:0.008043:0.005241:0.004637:0.014756:0.009152:0.010281:0.009152:0.005806:0.010281:0.009152:0.009152:0.005806:0.005806:0.010281:0.005806:0.009152:0.006914:0.004637:0.009152:0.009152:0.006914:0.009152:0.005806:0.010281:0.010281:0.015885:0.009152:0.004637:0.006914:0.014756:0.013647:0.013647:0.006914:0.004637:0.009152:0.010281:0.010281:0.004637:0.009152:0.010281:0.005806:0.010281:0.006914:0.009152:0.009152:0.005806:0.009152:0.005806:0.004637:0.009152:0.009152:0.010281:0.009152:0.009152:0.006914:0.004637:0.006914:0.013647:0.013647:0.013647:0.006914:0.004637:0.009152:0.006914:0.009152:0.004637:0.005806:0.014756:0.010281:0.004637:0.009152:0.010281:0.015885:0.015885:0.010281:0.010281:0.004637:0.009152:0.009152:0.010281:0.009152:0.009152:0.006914:0.007846:0.005040
that affect humans worldwide. The available therapeutic options suffer from many drawbacks :@0.104762:0.378888:0.900388:0.378888:0.900388:0.359688:0.104762:0.359688:0.005806:0.010281:0.009152:0.005806:0.006874:0.009152:0.006552:0.006914:0.009152:0.009152:0.005806:0.006874:0.010281:0.010281:0.015885:0.009152:0.010281:0.008043:0.006874:0.014756:0.010281:0.006914:0.005806:0.010281:0.014756:0.005806:0.010281:0.009152:0.005241:0.006509:0.012519:0.010281:0.009152:0.006874:0.009152:0.010281:0.009152:0.005806:0.005806:0.009152:0.010281:0.005806:0.009152:0.006874:0.005806:0.010281:0.009152:0.006914:0.009152:0.010281:0.009152:0.010281:0.005806:0.005806:0.009152:0.006874:0.010281:0.010281:0.005806:0.005806:0.010281:0.010281:0.008043:0.006874:0.008043:0.010281:0.006552:0.006914:0.009152:0.006914:0.006874:0.006914:0.006914:0.010281:0.015885:0.006874:0.015885:0.009152:0.010281:0.010281:0.006874:0.010281:0.006914:0.009152:0.014756:0.010281:0.009152:0.009152:0.010281:0.007846:0.005040
including high toxicity and decreased specificity. Therefore, there is a need for more effective :@0.104762:0.395992:0.900328:0.395992:0.900328:0.376792:0.104762:0.376792:0.005806:0.010281:0.009152:0.005806:0.010281:0.010281:0.005806:0.010281:0.010281:0.006471:0.010281:0.005806:0.010281:0.010281:0.006471:0.005806:0.010281:0.010281:0.005806:0.009152:0.005806:0.005806:0.010281:0.006471:0.009152:0.010281:0.010281:0.006471:0.010281:0.009152:0.009152:0.006914:0.009152:0.009152:0.008043:0.009152:0.010281:0.006471:0.008043:0.010281:0.009152:0.009152:0.005806:0.006914:0.005806:0.009152:0.005806:0.005806:0.008973:0.005241:0.006112:0.012519:0.010281:0.009152:0.006914:0.009152:0.006914:0.010281:0.006914:0.009152:0.005241:0.006471:0.005806:0.010281:0.009152:0.006914:0.009152:0.006471:0.005806:0.008043:0.006471:0.009152:0.006471:0.010281:0.009152:0.009152:0.010281:0.006471:0.006914:0.010281:0.006914:0.006471:0.015885:0.010281:0.006914:0.009152:0.006471:0.009152:0.006550:0.006914:0.009152:0.009152:0.005806:0.005806:0.010281:0.008948:0.005040
and safer therapeutic agents. A series of new pyrazolo[3,4-d]pyrimidine analogs was designed, :@0.104762:0.413096:0.900380:0.413096:0.900380:0.393897:0.104762:0.393897:0.009152:0.010281:0.010281:0.006108:0.008043:0.009152:0.006914:0.009152:0.006914:0.006108:0.005806:0.010281:0.009152:0.006914:0.009152:0.010281:0.009152:0.010281:0.005806:0.005806:0.009152:0.006108:0.009152:0.010281:0.009152:0.010281:0.005806:0.008043:0.005241:0.004993:0.013647:0.006108:0.008043:0.009152:0.006914:0.005806:0.009152:0.008043:0.006108:0.010281:0.006914:0.006108:0.010281:0.009152:0.014756:0.006108:0.010281:0.010281:0.006914:0.009152:0.009152:0.010281:0.005806:0.010281:0.006914:0.010281:0.005241:0.010281:0.006914:0.010281:0.006914:0.010281:0.010281:0.006914:0.005806:0.015885:0.005806:0.010281:0.005806:0.010281:0.009152:0.006108:0.009152:0.010281:0.009152:0.005806:0.010281:0.010281:0.008043:0.006108:0.014756:0.009152:0.008043:0.006108:0.010281:0.009152:0.008043:0.005806:0.010281:0.010281:0.009152:0.010281:0.005040:0.005040
synthesized, and evaluated as anticancer agents against the CRC and HCC cells, HCT116, and :@0.104762:0.430201:0.900455:0.430201:0.900455:0.411001:0.104762:0.411001:0.008043:0.010281:0.010281:0.005806:0.010281:0.009152:0.008043:0.005806:0.009152:0.009152:0.010281:0.005241:0.006169:0.009152:0.010281:0.010281:0.006169:0.009152:0.010281:0.009152:0.005806:0.010281:0.009152:0.005806:0.009152:0.010281:0.006158:0.009152:0.008043:0.006169:0.009152:0.010281:0.005806:0.005806:0.009152:0.009152:0.010281:0.009152:0.009152:0.006914:0.006169:0.009152:0.010281:0.009152:0.010281:0.005806:0.008043:0.006169:0.009152:0.010281:0.009152:0.005806:0.010281:0.008043:0.005806:0.006169:0.005806:0.010281:0.009152:0.006158:0.013647:0.013647:0.013647:0.006158:0.009152:0.010281:0.010281:0.006169:0.014756:0.013647:0.013647:0.006169:0.009152:0.009152:0.005806:0.005806:0.008043:0.005241:0.006169:0.014756:0.013647:0.012519:0.009533:0.010281:0.010281:0.005241:0.006169:0.009152:0.010281:0.010079:0.005040
HepG2, respectively. Pyrazolo[3,4-d]pyrimidinone derivatives bearing N5-2-(4-halophenyl) :@0.104762:0.447305:0.900346:0.447305:0.900346:0.428106:0.104762:0.428106:0.014756:0.009152:0.010281:0.014756:0.010281:0.005241:0.011410:0.006914:0.009152:0.008043:0.010281:0.009152:0.009152:0.005806:0.005806:0.010281:0.009152:0.005806:0.008971:0.005241:0.011410:0.011410:0.010281:0.006914:0.009152:0.009152:0.010281:0.005806:0.010281:0.006914:0.010281:0.005241:0.010281:0.006914:0.010281:0.006914:0.010281:0.010281:0.006914:0.005806:0.015885:0.005806:0.010281:0.005806:0.010281:0.010281:0.010281:0.009152:0.011410:0.010281:0.009152:0.006914:0.005806:0.010281:0.009152:0.005806:0.005806:0.010281:0.009152:0.008043:0.011410:0.010281:0.009152:0.009152:0.006914:0.005806:0.010281:0.010281:0.011410:0.014756:0.010281:0.006914:0.010281:0.006914:0.006914:0.010281:0.006914:0.010281:0.009152:0.005806:0.010281:0.010281:0.010281:0.009152:0.010281:0.010281:0.005806:0.006713:0.005040
acetamide substituents were identified as the most potent amongst evaluated compounds. Further :@0.104762:0.464410:0.900426:0.464410:0.900426:0.445210:0.104762:0.445210:0.009152:0.009152:0.009152:0.005806:0.009152:0.015885:0.005806:0.010281:0.009152:0.004253:0.008043:0.010281:0.010281:0.008043:0.005806:0.005806:0.005806:0.010281:0.009152:0.010281:0.005806:0.008043:0.004253:0.014756:0.009152:0.006914:0.009152:0.004253:0.005806:0.010281:0.009152:0.010281:0.005806:0.005806:0.006914:0.005806:0.009152:0.010281:0.004253:0.009152:0.008043:0.004253:0.005806:0.010281:0.009152:0.004253:0.015885:0.010281:0.008043:0.005806:0.004253:0.010281:0.010281:0.005806:0.009152:0.010281:0.005806:0.004253:0.009152:0.015885:0.010281:0.010281:0.010281:0.008043:0.005806:0.004253:0.009152:0.010281:0.009152:0.005806:0.010281:0.009152:0.005806:0.009152:0.010281:0.004253:0.009152:0.010281:0.015885:0.010281:0.010281:0.010281:0.010281:0.010281:0.008043:0.005241:0.004253:0.011410:0.010281:0.006914:0.005806:0.010281:0.009152:0.006713:0.005040
evaluation of CDK2 kinase inhibition of two potential cytotoxic compounds 4a and 4b confirmed :@0.104762:0.481514:0.900285:0.481514:0.900285:0.462314:0.104762:0.462314:0.009152:0.010281:0.009152:0.005806:0.010281:0.009152:0.005806:0.005806:0.010281:0.010281:0.004193:0.010281:0.006914:0.004193:0.013647:0.014756:0.014756:0.010281:0.004193:0.010281:0.005806:0.010281:0.009152:0.008043:0.009152:0.004193:0.005806:0.010281:0.010281:0.005806:0.010281:0.005806:0.005806:0.005806:0.010281:0.010281:0.004193:0.010281:0.006914:0.004193:0.005806:0.014756:0.010281:0.004193:0.010281:0.010281:0.005806:0.009152:0.010281:0.005806:0.005806:0.009152:0.005806:0.004193:0.009152:0.010281:0.005806:0.010281:0.005806:0.010281:0.010281:0.005806:0.009152:0.004193:0.009152:0.010281:0.015885:0.010281:0.010281:0.010281:0.010281:0.010281:0.008043:0.004193:0.010281:0.009152:0.004193:0.009152:0.010281:0.010281:0.004193:0.010281:0.010281:0.004193:0.009152:0.010281:0.010281:0.006914:0.005806:0.006914:0.015885:0.009152:0.010079:0.005040
their CDK2 inhibitory activity. Compound 4a was more potent than the reference roscovitine :@0.104762:0.498618:0.900467:0.498618:0.900467:0.479419:0.104762:0.479419:0.005806:0.010281:0.009152:0.005806:0.006914:0.007177:0.013647:0.014756:0.014756:0.010281:0.007177:0.005806:0.010281:0.010281:0.005806:0.010281:0.005806:0.005806:0.010281:0.006914:0.010281:0.007177:0.009152:0.009152:0.005806:0.005806:0.010281:0.005806:0.005806:0.008973:0.005241:0.007177:0.013647:0.010281:0.015885:0.010281:0.010281:0.010281:0.010281:0.010281:0.007177:0.010281:0.009152:0.007177:0.014756:0.009152:0.008043:0.007177:0.015885:0.010281:0.006914:0.009152:0.007177:0.010281:0.010281:0.005806:0.009152:0.010281:0.005806:0.007177:0.005806:0.010281:0.009152:0.010281:0.007177:0.005806:0.010281:0.009152:0.007177:0.006914:0.009152:0.006914:0.009152:0.006914:0.009152:0.010281:0.009152:0.009152:0.007177:0.006914:0.010281:0.008043:0.009152:0.010281:0.010281:0.005806:0.005806:0.005806:0.010281:0.008948:0.005040
regarding the CDK2 inhibitory activity (IC50 values: 0.21 and 0.25 µM, respectively). In :@0.104762:0.515723:0.900366:0.515723:0.900366:0.496523:0.104762:0.496523:0.006914:0.009152:0.010281:0.009152:0.006914:0.010281:0.005806:0.010281:0.010281:0.009717:0.005806:0.010281:0.009152:0.009717:0.013647:0.014756:0.014756:0.010281:0.009717:0.005806:0.010281:0.010281:0.005806:0.010281:0.005806:0.005806:0.010281:0.006914:0.010281:0.009717:0.009152:0.009152:0.005806:0.005806:0.010281:0.005806:0.005806:0.010281:0.009717:0.006914:0.006914:0.013647:0.010281:0.010281:0.009717:0.010281:0.009152:0.005806:0.010281:0.009152:0.008043:0.005806:0.009717:0.010281:0.005241:0.010281:0.010281:0.009717:0.009152:0.010281:0.010281:0.009717:0.010281:0.005241:0.010281:0.010281:0.009717:0.011813:0.018123:0.005241:0.009717:0.006914:0.009152:0.008043:0.010281:0.009152:0.009152:0.005806:0.005806:0.010281:0.009152:0.005806:0.010281:0.006914:0.005241:0.009717:0.006914:0.010079:0.005040
silico molecular docking provided insights into the molecular interactions of compounds 4a :@0.104762:0.532827:0.900422:0.532827:0.900422:0.513627:0.104762:0.513627:0.008043:0.005806:0.005806:0.005806:0.009152:0.010281:0.008346:0.015885:0.010281:0.005806:0.009152:0.009152:0.010281:0.005806:0.009152:0.006914:0.008346:0.010281:0.010281:0.009152:0.010281:0.005806:0.010281:0.010281:0.008346:0.010281:0.006914:0.010281:0.010281:0.005806:0.010281:0.009152:0.010281:0.008346:0.005806:0.010281:0.008043:0.005806:0.010281:0.010281:0.005806:0.008043:0.008346:0.005806:0.010281:0.005806:0.010281:0.008346:0.005806:0.010281:0.009152:0.008346:0.015885:0.010281:0.005806:0.009152:0.009152:0.010281:0.005806:0.009152:0.006914:0.008346:0.005806:0.010281:0.005806:0.009152:0.006914:0.009152:0.009152:0.005806:0.005806:0.010281:0.010281:0.008043:0.008346:0.010281:0.006914:0.008346:0.009152:0.010281:0.015885:0.010281:0.010281:0.010281:0.010281:0.010281:0.008043:0.008346:0.010281:0.008946:0.005040
and 4b with important amino acids within the ATP-binding site of CDK2 (Ile10, Leu83, and :@0.104762:0.549931:0.900311:0.549931:0.900311:0.530732:0.104762:0.530732:0.009152:0.010281:0.010281:0.007499:0.010281:0.010281:0.007499:0.014756:0.005806:0.005806:0.010281:0.007499:0.005806:0.015885:0.010281:0.010281:0.006914:0.005806:0.009152:0.010281:0.005806:0.007499:0.009152:0.015885:0.005806:0.010281:0.010281:0.007499:0.009152:0.009152:0.005806:0.010281:0.008043:0.007499:0.014756:0.005806:0.005806:0.010281:0.005806:0.010281:0.007499:0.005806:0.010281:0.009152:0.006390:0.012525:0.012519:0.011410:0.006914:0.010281:0.005806:0.010281:0.010281:0.005806:0.010281:0.010281:0.007499:0.008043:0.005806:0.005806:0.009152:0.007499:0.010281:0.006914:0.007499:0.013647:0.014756:0.014756:0.010281:0.007499:0.006914:0.006914:0.005806:0.009152:0.010281:0.010281:0.005241:0.007499:0.012519:0.009152:0.010281:0.010281:0.010281:0.005241:0.007499:0.009152:0.010281:0.010079:0.005040
Leu134). Overall, compounds 4a and 4b were identified as interesting CDK2 inhibitors eliciting :@0.104762:0.567036:0.900305:0.567036:0.900305:0.547836:0.104762:0.547836:0.012519:0.009152:0.010281:0.010281:0.010281:0.010281:0.006914:0.005241:0.004979:0.014756:0.010281:0.009152:0.006914:0.009152:0.005806:0.005806:0.005241:0.004979:0.009152:0.010281:0.015885:0.010281:0.010281:0.010281:0.010281:0.010281:0.008043:0.004979:0.010281:0.009152:0.004979:0.009152:0.010281:0.010281:0.004979:0.010281:0.010281:0.004979:0.014756:0.009152:0.006914:0.009152:0.004979:0.005806:0.010281:0.009152:0.010281:0.005806:0.005806:0.006914:0.005806:0.009152:0.010281:0.004979:0.009152:0.008043:0.004979:0.005806:0.010281:0.005806:0.009152:0.006914:0.009152:0.008043:0.005806:0.005806:0.010281:0.010281:0.004979:0.013647:0.014756:0.014756:0.010281:0.004979:0.005806:0.010281:0.010281:0.005806:0.010281:0.005806:0.005806:0.010281:0.006914:0.008043:0.004979:0.009152:0.005806:0.005806:0.009152:0.005806:0.005806:0.005806:0.010281:0.010079:0.005040
antiproliferative activity against the CRC and HCC cells, HCT116 and HepG2, respectively, for :@0.104762:0.584140:0.900386:0.584140:0.900386:0.564941:0.104762:0.564941:0.009152:0.010281:0.005806:0.005806:0.010281:0.006914:0.010281:0.005806:0.005806:0.006914:0.009152:0.006914:0.009152:0.005806:0.005806:0.010281:0.009152:0.005221:0.009152:0.009152:0.005806:0.005806:0.010281:0.005806:0.005806:0.010281:0.005221:0.009152:0.010281:0.009152:0.005806:0.010281:0.008043:0.005806:0.005221:0.005806:0.010281:0.009152:0.005221:0.013647:0.013647:0.013647:0.005221:0.009152:0.010281:0.010281:0.005221:0.014756:0.013647:0.013647:0.005221:0.009152:0.009152:0.005806:0.005806:0.008043:0.005241:0.005221:0.014756:0.013647:0.012519:0.009533:0.010281:0.010281:0.005221:0.009152:0.010281:0.010281:0.005221:0.014756:0.009152:0.010281:0.014756:0.010281:0.005241:0.005221:0.006914:0.009152:0.008043:0.010281:0.009152:0.009152:0.005806:0.005806:0.010281:0.009152:0.005806:0.008973:0.005241:0.005221:0.006914:0.010281:0.006713:0.005040
future further investigations and development.:@0.104762:0.601245:0.494279:0.601245:0.494279:0.582045:0.104762:0.582045:0.006914:0.010281:0.005806:0.010281:0.006914:0.009152:0.006995:0.006914:0.010281:0.006914:0.005806:0.010281:0.009152:0.006914:0.006995:0.005806:0.010281:0.010281:0.009152:0.008043:0.005806:0.005806:0.010281:0.009152:0.005806:0.005806:0.010281:0.010281:0.008043:0.006995:0.009152:0.010281:0.010281:0.006985:0.010281:0.009152:0.010281:0.009152:0.005806:0.010281:0.010281:0.015885:0.009152:0.010281:0.005806:0.005040
111:@0.864761:0.971012:0.911903:0.971012:0.911903:0.940075:0.864761:0.940075:0.015300:0.015300:0.016540